DXCM · DEXCOM INC · Top AI ETF

Back to holdings

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.

Close · 3M

+16.98%

Held by 0 AI ETFs

None of the tracked AI ETFs currently hold this name.

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals15

Win rate40% (6/15)

Avg buy return+2.02%

LQAIno longer held18 signals

LQAI · Exit · 1d

weight 0.700% → 0 (exited)·stock down 4.6% in the 30 days before

Sep 29·entry $86.64·now $85.92

-0.83%

since Sep 29

LQAI · Accumulation · 5d

weight 0.670% → 0.720% (+0.050 pp)·stock down 0.6% in the 30 days before

Sep 18·entry $89.35·now $85.92Fresh

-3.84%

since Sep 18

LQAI · Weight increase · 3d

weight 0.670% → 0.720% (+0.050 pp)·stock down 1.6% in the 30 days before

Sep 16·entry $87.34·now $85.92Fresh

-1.63%

since Sep 16

LQAI · Weight increase · 2d

weight 0.670% → 0.710% (+0.040 pp)·stock down 3.7% in the 30 days before

Sep 15·entry $86.45·now $85.92Fresh

-0.61%

since Sep 15

LQAI · Weight decrease · 5d

weight 0.790% → 0.670% (-0.120 pp)·stock down 0.3% in the 30 days before

Sep 8·entry $84.53·now $85.92

+1.64%

since Sep 8

LQAI · Weight decrease · 4d

weight 0.790% → 0.700% (-0.090 pp)·stock up 5.9% in the 30 days before

Sep 4·entry $87.90·now $85.92

-2.25%

since Sep 4

LQAI · Weight decrease · 3d

weight 0.790% → 0.720% (-0.070 pp)·stock up 8.5% in the 30 days before

Sep 3·entry $89.71·now $85.92

-4.22%

since Sep 3

LQAI · Weight decrease · 2d

weight 0.790% → 0.730% (-0.060 pp)·stock up 3.2% in the 30 days before

Sep 2·entry $89.69·now $85.92

-4.20%

since Sep 2

LQAI · Weight decrease · 2d

weight 0.800% → 0.770% (-0.030 pp)·stock up 18.9% in the 30 days before

Aug 26·entry $88.96·now $85.92

-3.42%

since Aug 26

LQAI · Weight increase · 2d

weight 0.750% → 0.780% (+0.030 pp)·stock up 20.2% in the 30 days before

Aug 19·entry $89.88·now $85.92Fresh

-4.41%

since Aug 19

LQAI · Weight decrease · 3d

weight 0.790% → 0.750% (-0.040 pp)·stock up 15.8% in the 30 days before

Aug 17·entry $88.76·now $85.92

-3.20%

since Aug 17

LQAI · Accumulation · 5d

weight 0.730% → 0.760% (+0.030 pp)·stock up 15.1% in the 30 days before

Aug 14·entry $89.75·now $85.92Fresh

-4.27%

since Aug 14

LQAI · Accumulation · 5d

weight 0.730% → 0.780% (+0.050 pp)·stock up 25.8% in the 30 days before

Aug 13·entry $91.48·now $85.92Fresh

-6.08%

since Aug 13

LQAI · Accumulation · 5d

weight 0.730% → 0.790% (+0.060 pp)·stock up 22.5% in the 30 days before

Aug 12·entry $90.80·now $85.92Fresh

-5.37%

since Aug 12

LQAI · Weight increase · 4d

weight 0 → 0.780% (new)·stock up 17.3% in the 30 days before

Aug 11·entry $89.53·now $85.92Fresh

-4.03%

since Aug 11

LQAI · Weight increase · 3d

weight 0 → 0.770% (new)·stock up 16.9% in the 30 days before

Aug 10·entry $87.65·now $85.92Fresh

-1.97%

since Aug 10

LQAI · Weight increase · 2d

weight 0 → 0.740% (new)·stock up 16.1% in the 30 days before

Aug 7·entry $84.75·now $85.92Fresh

+1.38%

since Aug 7

LQAI · New entry · 1d

weight 0 → 0.730% (new)·stock up 12.1% in the 30 days before

Aug 6·entry $83.02·now $85.92Drifting

+3.49%

since Aug 6

AIEQno longer held2 signals

AIEQ · Exit · 1d

weight 0.240% → 0 (exited)·stock up 21.2% in the 30 days before

Aug 2·entry $87.31·now $85.92

-1.59%

since Aug 2

AIEQ · Weight decrease · 2d

stock up 2.3% in the 30 days before

Jul 23·entry $70.48·now $85.92

+21.91%

since Jul 23

AIVLno longer held10 signals

AIVL · Exit · 1d

weight 0.342% → 0 (exited)·stock up 21.2% in the 30 days before

Jul 31·entry $83.45·now $85.92

+2.96%

since Jul 31

AIVL · Weight increase · 3d

stock up 7.4% in the 30 days before

Jul 29·entry $75.14·now $85.92Chased

+14.35%

since Jul 29

AIVL · Weight increase · 2d

stock up 6.7% in the 30 days before

Jul 28·entry $74.85·now $85.92Chased

+14.79%

since Jul 28

AIVL · Weight decrease · 5d

stock up 2.3% in the 30 days before

Jul 23·entry $70.48·now $85.92

+21.91%

since Jul 23

AIVL · Weight decrease · 4d

stock up 3.4% in the 30 days before

Jul 22·entry $71.43·now $85.92

+20.29%

since Jul 22

AIVL · Weight decrease · 3d

stock up 3.1% in the 30 days before

Jul 21·entry $74.75·now $85.92

+14.94%

since Jul 21

AIVL · Weight decrease · 2d

stock up 6.3% in the 30 days before

Jul 20·entry $75.69·now $85.92

+13.52%

since Jul 20

AIVL · Weight decrease · 2d

stock down 3.5% in the 30 days before

Jul 15·entry $72.73·now $85.92

+18.14%

since Jul 15

AIVL · Accumulation · 5d

stock down 1.5% in the 30 days before

Jul 14·entry $74.12·now $85.92Chased

+15.92%

since Jul 14

AIVL · Accumulation · 6d

stock up 2.1% in the 30 days before

Jul 13·entry $76.35·now $85.92Chased

+12.53%

since Jul 13

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of May 2

The AI ETFs, specifically AIVL, are showing a recent trend of decreasing their weight in Dexcom. This observed selling activity aligns with the framework's 'Fail' verdict, which primarily stems from concerns regarding a lack of sufficient margin of safety at the current price and incomplete financial health data.

Circle of CompetenceThe unit economics of continuous glucose monitoring, with recurring sensor sales for a chronic condition, appear sufficiently stable and predictable for reasonable ten-year cash flow projections.
Economic MoatDexcom benefits from a durable economic moat comprised of strong brand recognition, patient and provider switching costs, and regulatory and patent barriers to entry in the medical device market.
ManagementThe provided financial data is insufficient to assess management's candor, capital allocation discipline, or their personal stake in the company.
Financial HealthDespite a strong recent ROE, the absence of 10-year ROE data, operating margins, detailed debt figures, and owner earnings prevents a comprehensive assessment against the framework's financial health criteria.
Margin of SafetyThe current valuation multiples for Dexcom (PER 28.38, PBR 9.43, EV/EBITDA 22.39) appear high, making it difficult to identify a defensible discount to intrinsic value for a sufficient margin of safety.

Dexcom operates within a predictable circle of competence and possesses a strong economic moat, suggesting a high-quality business. However, the framework's assessment is hindered by insufficient data to evaluate management and key aspects of financial health, leading to a 'Fail' on that stage. Moreover, the current valuation does not present a clear margin of safety, resulting in an overall 'Fail' verdict.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.